Portfoliotracker

Savara Inc.

SVRA · NASDAQGS · Healthcare Biotechnology 17/100 E

4,465 $
▼ −0,175 (−3,77 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:07
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score17 / 100 Market cap1,14 mld. $ P/E– Forward P/E-12,1 P/S– P/B10,5 EV/EBITDA– Dividend yield– FCF yield-11,54 % EPS-0,60 $ Net margin0,0 % Return on equity-151,0 % Beta0,30 Debt / equity0,29
52-week range 4,13 to 7,01
3-month average volume2,3 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Employees
70
Country
United States
Fiscal year end
31. 12.
Data since
28. 4. 2017

Explore further

Similar companies AQSTSLDBXERSOVID

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account